Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Blood Test

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   44352   clinical trials with a EudraCT protocol, of which   7379   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    14,202 result(s) found for: Blood Test. Displaying page 231 of 711.
    «« First « Previous 227  228  229  230  231  232  233  234  235  Next» Last»»
    EudraCT Number: 2007-000535-26 Sponsor Protocol Number: P05133 Start Date*: 2007-06-04
    Sponsor Name:SCHERING-PLOUGH
    Full Title: SwiTching from etAnercept to iNfliximab in the treatment of moderate to severe psoriasis; a multi-center, open label trial evaluating the efficacy, tOlerance and safety (TANGO)
    Medical condition: Patients with moderate to severe psoriasi.
    Disease: Version SOC Term Classification Code Term Level
    9.1 10037153 Psoriasis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2004-004728-11 Sponsor Protocol Number: MR/EUM202 Start Date*: 2005-03-25
    Sponsor Name:Avera Pharmaceuticals Inc.
    Full Title: A Multicenter, Randomized, Controlled, Observer-Blinded, Dose-Response Study to Evaluate The Efficacy in Tracheal Intubation and Safety of Gantacurium Chloride for Injection in Healthy Adult Patien...
    Medical condition: Adjunct to anesthesia to facilitate tracheal intubation (non-depolarizing neuromuscular blocking agent)
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: GB (Completed) DE (Completed) DK (Completed)
    Trial results: (No results available)
    EudraCT Number: 2011-000601-49 Sponsor Protocol Number: ICR-CTSU/2011/10030 Start Date*: 2012-03-14
    Sponsor Name:The Institute of Cancer Research [...]
    1. The Institute of Cancer Research
    2. Royal Marsden NHS Foundation Trust
    Full Title: TOPARP: Phase II Trial of Olaparib in Patients with Advanced Castration Resistant Prostate Cancer.
    Medical condition: Advanced Castration Resistant Prostate Cancer
    Disease: Version SOC Term Classification Code Term Level
    18.0 100000004864 10036910 Prostate cancer NOS LLT
    Population Age: Adults, Elderly Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: (No results available)
    EudraCT Number: 2017-002875-25 Sponsor Protocol Number: NEO-CIRC-003 Start Date*: 2018-07-24
    Sponsor Name:SERMAS-FIBHULP
    Full Title: An international multicentre randomized placebo-controlled, double blind three arm trial to investigate the efficacy of dobutamine with two different starting doses in the treatment of haemodynamic...
    Medical condition: Haemodynamic insufficiency (Haemodynamic insufficiency after birth is commonly seen in babies born prematurely. The condition has a significant clinical impact. A final common pathway is seen but ...
    Disease: Version SOC Term Classification Code Term Level
    20.0 10047065 - Vascular disorders 10009196 Circulatory failure neonatal PT
    Population Age: Preterm newborn infants, Under 18 Gender: Male, Female
    Trial protocol: ES (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2007-000766-20 Sponsor Protocol Number: CICL670A2206 Start Date*: 2008-07-17
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A multicenter, randomized, open-label phase II trial evaluating deferasirox compared with deferoxamine in patients with cardiac iron overload due to chronic blood transfusions
    Medical condition: Beta-thalassemia major (TM) or Diamond Blackfan anemia (DBA) or myelodysplastic syndromes (MDS) (low and INT-1 risk as per the IPSS for MDS) or sideroblastic anemia and myocardial iron overload as ...
    Disease:
    Population Age: Children, Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) IT (Completed)
    Trial results: View results
    EudraCT Number: 2011-001424-38 Sponsor Protocol Number: EFC11716 Start Date*: 2012-08-03
    Sponsor Name:sanofi-aventis Recherche & Développement
    Full Title: A Randomized, Double-Blind, Active-Controlled, Parallel-Group Study to Evaluate the Efficacy and Safety of SAR236553/REGN727 over 24 weeks in Patients with Hypercholesterolemia
    Medical condition: Hypercholesterolaemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10027433 - Metabolism and nutrition disorders 10020603 Hypercholesterolaemia PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) FI (Completed) NL (Completed)
    Trial results: View results
    EudraCT Number: 2014-000360-17 Sponsor Protocol Number: TGO-VGB-III-01 Start Date*: Information not available in EudraCT
    Sponsor Name:TARGEON
    Full Title: Acceptability study of a new paediatric form of vigabatrin in infants and children with infantile spasms or pharmaco-resistant partial epilepsy. Observational, descriptive, open-label, multi-centr...
    Medical condition: Infantile spasms and pharmaco-resistant partial epilepsy
    Disease: Version SOC Term Classification Code Term Level
    18.0 10029205 - Nervous system disorders 10021750 Infantile spasms PT
    18.0 10029205 - Nervous system disorders 10065336 Partial epilepsy LLT
    Population Age: Infants and toddlers, Children, Under 18 Gender: Male, Female
    Trial protocol: FR (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2012-005019-14 Sponsor Protocol Number: 12076 Start Date*: 2013-05-03
    Sponsor Name:University of Nottingham
    Full Title: The short term effects of an AKT inhibitor (AZD5363) on biomarkers of the AKT pathway and anti-tumour activity in a breast cancer paired biopsy study (STAKT Trial)
    Medical condition: primary breast cancer
    Disease: Version SOC Term Classification Code Term Level
    18.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10057654 Breast cancer female PT
    Population Age: Adults, Elderly Gender: Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2013-003742-16 Sponsor Protocol Number: IB1001-04 Start Date*: 2014-04-29
    Sponsor Name:Cangene Europe Limited
    Full Title: Pharmacokinetics, Safety and Efficacy of Recombinant Factor IX Product, IB1001, in Patients with Severe Hemophilia B
    Medical condition: Severe Hemophilia B
    Disease: Version SOC Term Classification Code Term Level
    16.0 100000004850 10018939 Haemophilia B (Factor IX) LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2012-003190-26 Sponsor Protocol Number: RESTART13 Start Date*: 2013-01-14
    Sponsor Name:ACCORD (Academic and Clinical Central Office for Research & Development) [...]
    1. ACCORD (Academic and Clinical Central Office for Research & Development)
    2. ACCORD (Academic and Clinical Central Office for Research & Development)
    Full Title: REstart or STop Antithrombotics Randomised Trial (RESTART)
    Medical condition: Spontaneous Intracerebral Haemorrhage (ICH)
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004852 10022753 Intracerebral haemorrhage LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA)
    Trial results: View results
    EudraCT Number: 2013-000872-14 Sponsor Protocol Number: UCL/11/0519 Start Date*: 2013-07-23
    Sponsor Name:University College London
    Full Title: Adoptive Immunotherapy with CD25/71 allodepleted donor T cells to improve immunity after unrelated donor stem cell transplant (ICAT)
    Medical condition: acute myeloid or acute lymphoblastic leukaemia
    Disease: Version SOC Term Classification Code Term Level
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000880 Acute myeloid leukaemia PT
    16.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10000844 Acute lymphoblastic leukaemia LLT
    Population Age: Adolescents, Under 18, Adults Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2015-003614-24 Sponsor Protocol Number: CLTT462X2101 Start Date*: 2016-03-16
    Sponsor Name:Novartis Pharma Services AG
    Full Title: A phase I dose finding study of oral LTT462 in adult patients with advanced solid tumors harboring MAPK pathway alterations
    Medical condition: Adult and adolescent patients with advanced solid tumors harboring MAPK pathway alterations
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Prematurely Ended) NL (Prematurely Ended) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2013-003295-12 Sponsor Protocol Number: 15022013 Start Date*: 2013-10-31
    Sponsor Name:Roskilde University Hospital
    Full Title: Combination Therapy Interferon Alpha + JAK1-2 Inhibitor in The Ph-Negative Chronic Myeloid Neoplasms
    Medical condition:
    Disease: Version SOC Term Classification Code Term Level
    18.1 100000004864 10028538 Myelofibrosis with myelometaplasia LLT
    18.1 100000004864 10036061 Polycythemia vera LLT
    18.1 100000004864 10053134 Osteomyelofibrosis LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2020-001595-15 Sponsor Protocol Number: 270389-010520 Start Date*: 2020-06-23
    Sponsor Name:Henrik Birn
    Full Title: The Measures to Optimize RAAS-blockade in Patients with Hyperkalemia and Chronic Kidney Disease
    Medical condition: Chronic kidney disease with albuminuria
    Disease: Version SOC Term Classification Code Term Level
    23.1 10038359 - Renal and urinary disorders 10064848 Chronic kidney disease PT
    21.1 100000004861 10020647 Hyperkalemia LLT
    20.0 10038359 - Renal and urinary disorders 10001580 Albuminuria PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DK (Completed)
    Trial results: View results
    EudraCT Number: 2014-000274-20 Sponsor Protocol Number: GNT-WAS-03 Start Date*: 2014-05-14
    Sponsor Name:Genethon
    Full Title: LONG TERM SAFETY FOLLOW UP OF PATIENTS ENROLLED IN THE PHASE I/II CLINICAL TRIAL OF HAEMATOPOIETIC STEM CELL GENE THERAPY FOR THE WISKOTT-ALDRICH SYNDROME(GTG 002-07 AND GTG 003-08)
    Medical condition: Wiskott-Aldrich syndrome (WAS) is a rare X-linked immunodeficiency caused by mutations in a single gene ,the Wiskott-Aldrich Syndrome Protein (WASP). WAS is characterised by micro-thrombocytopeni...
    Disease: Version SOC Term Classification Code Term Level
    19.1 10010331 - Congenital, familial and genetic disorders 10047992 Wiskott-Aldrich syndrome PT
    Population Age: Children, Adolescents, Under 18, Adults Gender: Male
    Trial protocol: GB (GB - no longer in EU/EEA) FR (Trial now transitioned)
    Trial results: (No results available)
    EudraCT Number: 2004-002955-14 Sponsor Protocol Number: ISRCTN86750102 Start Date*: 2008-07-28
    Sponsor Name:London School of Hygiene and Tropical Medicine [...]
    1. London School of Hygiene and Tropical Medicine
    2. World Health Organisation
    Full Title: A large randomised placebo controlled trial among trauma patients with or at risk of significant haemorrhage, of the effects of antifibrinolytic treatment on death and transfusion requirement
    Medical condition: Haemorrhage following Trauma
    Disease:
    Population Age: Adolescents, Under 18, Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed) BE (Completed) SK (Completed) PT (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2016-004352-30 Sponsor Protocol Number: AB1601 Start Date*: 2017-05-22
    Sponsor Name:Araclon Biotech, S.L.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled, 24 months Study in Patients with amnestic Mild Cognitive Impairment or Very Mild Alzheimer’s Disease to Investigate the Safety, Tolerabi...
    Medical condition: Alzheimer's disease
    Disease: Version SOC Term Classification Code Term Level
    19.1 100000004852 10001896 Alzheimer's disease LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: ES (Ongoing) SE (Completed) FR (Completed) IT (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2020-004231-25 Sponsor Protocol Number: MS201923_0050 Start Date*: 2024-05-21
    Sponsor Name:Merck Healthcare KGaA
    Full Title: A Phase II, open-label, single-arm study of berzosertib (M6620) in combination with topotecan in participants with relapsed platinum-resistant small-cell lung cancer
    Medical condition: Relapsed platinum resistant small-cell lung cancer
    Disease: Version SOC Term Classification Code Term Level
    21.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10041067 Small cell lung cancer PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: FR (Completed) IT (Completed) ES (Temporarily Halted)
    Trial results: View results
    EudraCT Number: 2008-004083-39 Sponsor Protocol Number: DSMM_XIII Start Date*: 2009-10-19
    Sponsor Name:GMIHO Gesellschaft für Medizinische Innovation – Hämatologie und Onkologie mbH
    Full Title: The combination of Lenalidomide and Dexamethasone with or without intensification by high-dose Melphalan in the treatment of multiple myeloma
    Medical condition: primary treatment of multiple myeloma patients of age 60 till 75 years
    Disease: Version SOC Term Classification Code Term Level
    21.0 100000004864 10028228 Multiple myeloma LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed)
    Trial results: View results
    EudraCT Number: 2015-003225-33 Sponsor Protocol Number: ACE-536-B-THAL-002 Start Date*: 2018-01-08
    Sponsor Name:Celgene Corporation
    Full Title: A Phase 2, Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Determine the Efficacy and Safety of Luspatercept (ACE-536) versus Placebo in Adults with Non Transfusion Dependent Bet...
    Medical condition: Non transfusion dependent β-thalassemia
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004850 10074356 Non-transfusion dependent thalassemia LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) GR (Completed) IT (Completed)
    Trial results: View results
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    «« First « Previous 227  228  229  230  231  232  233  234  235  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sat Aug 02 09:34:41 CEST 2025 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA